Intercept shakeup continues as CMO, former NASH chief resigns. Is the NASH biotech abandoning its flagship disease?
First, they said goodbye to their founding CEO after 18 years. Now, Intercept is losing its CMO too, an executive who led the company’s flagship NASH program for much of its clinical development.
Intercept revealed in an SEC filing Monday that Jason Campagna tendered his resignation and will leave the company on March 5. His departure comes three months after the company abruptly announced they were replacing longtime CEO Mark Pruzanski with COO and former Sanofi commercial chief Jerry Durso.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.